Buchumschlag

Improved survival with MEK inhibition in BRAF-mutated melanoma

About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.2 Before 2010, no systemic therapy had be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Flaherty, Keith T. (VerfasserIn) , Hassel, Jessica C. (VerfasserIn) , Utikal, Jochen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 4, 2012
In: The New England journal of medicine
Year: 2012, Jahrgang: 367, Heft: 2, Pages: 107-114
ISSN:1533-4406
DOI:10.1056/NEJMoa1203421
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1203421
Volltext
Verfasserangaben:Keith T. Flaherty, M.D., Caroline Robert, M.D., Ph.D., Peter Hersey, M.D., Ph.D., Paul Nathan, M.D., Ph.D., Claus Garbe, M.D., Mohammed Milhem, M.B., Lev V. Demidov, M.D., Jessica C. Hassel, M.D., Piotr Rutkowski,M.D., Peter Mohr, M.D., Reinhard Dummer, M.D., Uwe Trefzer, M.D., James M.G. Larkin, M.D., Jochen Utikal, M.D., Brigitte Dreno, M.D., Marta Nyakas, M.D., Mark R. Middleton, Ph.D., Jürgen C. Becker, M.D., Ph.D., Michelle Casey, Ph.D., Laurie J. Sherman, R.N., Frank S. Wu, M.D., Ph.D., Daniele Ouellet, Ph.D., Anne-Marie Martin, Ph.D., Kiran Patel, Ph.D., and Dirk Schadendorf M.D., for the METRIC Study Group*
Beschreibung
Zusammenfassung:About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.2 Before 2010, no systemic therapy had been shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug.3 Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and vemurafenib, a selective BRAF inhibitor, have both been shown to improve survival among patients with metastatic melanoma . . .
Beschreibung:Gesehen am 21.08.2019
Beschreibung:Online Resource
ISSN:1533-4406
DOI:10.1056/NEJMoa1203421

Ähnliche Einträge